Cross-source evidence timeline
Dalbavancin research timeline
Follow 46 selected, directly cited source records from October 12, 2009 through October 10, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.↗
PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 21, 2021 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06810583↗
PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.↗
PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 1, 2026 · day precisionAdded to PeptideScanner November 16, 2026Regulatory
Federal Register notice 2026-15149↗
The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗
Added to PeptideScanner November 17, 2026Clinical trials
ClinicalTrials.gov record NCT05046860↗
PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026Regulatory
Drugs@FDA application ANDA219604↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026Literature metadata
[Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.↗
PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 23, 2025 · day precisionAdded to PeptideScanner November 16, 2026Regulatory
Drugs@FDA application ANDA218602↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026Literature metadata
Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.↗
PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 27, 2020 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.↗
PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 3, 2020 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
The current and future off-label uses of dalbavancin: a narrative review.↗
PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 2023 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2025
Regulatory
Drugs@FDA application ANDA218929↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026Regulatory
Drugs@FDA application ANDA217591↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026Regulatory
Drugs@FDA application ANDA219465↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026Literature metadata
Dalbavancin for the treatment of bone and joint infections: A meta-analysis.↗
PubMed lists PMID 39029624 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 17, 2024 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.↗
PubMed lists PMID 40001365 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 23, 2025 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2024
Clinical trials
ClinicalTrials.gov record NCT02814916↗
PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review.↗
PubMed lists PMID 38533780 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Letter, Review, with publication-date metadata of 2024-03-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 27, 2024 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.↗
PubMed lists PMID 38449918 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2024-02-07 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 7, 2024 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2023
Literature metadata
A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.↗
PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 28, 2023 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalbavancin in Bone and Joint Infections: A Systematic Review.↗
PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 15, 2023 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Global trends of dalbavancin: A bibliometric analysis.↗
PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 23, 2022 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2022
Literature metadata
Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.↗
PubMed lists PMID 35353020 in Expert review of anti-infective therapy as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-04-08 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 8, 2022 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04959799↗
PeptideScanner retained ClinicalTrials.gov record NCT04959799 at 2026-11-16T17:37:42.807Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.↗
PubMed lists PMID 34923922 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 19, 2021 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2021
Literature metadata
Dalbavancin.↗
PubMed lists PMID 34598419 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Journal Article, Review, with publication-date metadata of 2021-09-30 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 30, 2021 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.↗
PubMed lists PMID 34072670 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-05-31 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 31, 2021 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.↗
PubMed lists PMID 33962065 in Journal of global antimicrobial resistance as Journal Article, Review, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 4, 2021 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalbavancin for the management of osteomyelitis: a major step forward?↗
PubMed lists PMID 32457989 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2020-10-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 1, 2020 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.↗
PubMed lists PMID 31087630 in Clinical pharmacology in drug development as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-14 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 14, 2019 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Current trends in the real-life use of dalbavancin: report of a study panel.↗
PubMed lists PMID 32721599 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 25, 2020 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).↗
PubMed lists PMID 32223465 in Expert review of anti-infective therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2020-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 29, 2020 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT02961764↗
PeptideScanner retained ClinicalTrials.gov record NCT02961764 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-04-10, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03233438↗
PeptideScanner retained ClinicalTrials.gov record NCT03233438 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-01-18, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026
Source year
2019
Literature metadata
The role of dalbavancin in skin and soft tissue infections.↗
PubMed lists PMID 29298166 in Current opinion in infectious diseases as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 2018 · month precisionAdded to PeptideScanner November 16, 2026Regulatory
Federal Register notice 2019-09007↗
The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗
Added to PeptideScanner November 17, 2026Clinical trials
ClinicalTrials.gov record NCT02685033↗
PeptideScanner retained ClinicalTrials.gov record NCT02685033 at 2026-11-16T17:37:42.807Z. Its registry update date was 2019-01-04, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026
Source year
2018
Clinical trials
ClinicalTrials.gov record NCT02127970↗
PeptideScanner retained ClinicalTrials.gov record NCT02127970 at 2026-11-16T17:37:42.807Z. Its registry update date was 2018-09-28, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026Literature metadata
The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery.↗
PubMed lists PMID 29168673 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2017-11-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 23, 2017 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.↗
PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 25, 2017 · day precisionAdded to PeptideScanner November 16, 2026Regulatory
Federal Register notice 2018-02768↗
The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗
Added to PeptideScanner November 17, 2026
Source year
2015
Clinical trials
ClinicalTrials.gov record NCT01946568↗
PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026
Source year
2014
Regulatory
Drugs@FDA application NDA021883↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026Regulatory
Federal Register notice 2014-02942↗
The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗
Added to PeptideScanner November 17, 2026Clinical trials
ClinicalTrials.gov record NCT01339091↗
PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026
Source year
2009
Clinical trials
ClinicalTrials.gov record NCT00678106↗
PeptideScanner retained ClinicalTrials.gov record NCT00678106 at 2026-11-16T17:37:42.807Z. Its registry update date was 2009-10-12, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Added to PeptideScanner November 16, 2026